45
Participants
Start Date
November 28, 2017
Primary Completion Date
April 17, 2024
Study Completion Date
April 17, 2024
Binimetinib
Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
New York University Medical Center, New York
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
National Institute of Health - National Cancer Institute, Bethesda
Johns Hopkins University, Baltimore
University of Alabama at Birmingham, Birmingham
Nationwide Children's Hospital, Columbus
Ohio State University, Columbus
Cinncinnati Children's Hospital Medical Center, Cincinnati
Indiana University, Indianapolis
Lurie Children's Hospital of Chicago, Chicago
University of Chicago, Chicago
Washington University School of Medicine, St Louis
University of Utah, Salt Lake City
Children's Hospital of Los Angeles, Los Angeles
University of California at Los Angeles, Los Angeles
University of California, San Diego - Rady Children's Hospital, San Diego
University of California, San Francisco, San Francisco
UCSF Benioff Children's Hospital Oakland, Oakland
Oregon Health and Science University Hospital, Portland
University of Washington - Seattle Children's Hospital, Seattle
Boston Children's Hospital / Dana Farber Cancer Institute / Massachusetts General Hospital, Boston
Collaborators (1)
Array BioPharma
INDUSTRY
Pacific Pediatric Neuro-Oncology Consortium
OTHER
University of Alabama at Birmingham
OTHER